Multiple Sclerosis
Warwick Evidence is developing a speciality for MS-related projects and has undertaken the following multiple sclerosis appraisals:
- Ofatumumab for treating relapsing multiple sclerosis (TA699)
- Siponimod for treating secondary progressive multiple sclerosis (ID1304)
- Beta interferon and glatiramer acetate for multiple sclerosis (review of TA32) (ID809)
- Daclizumab for treating relapsing-remitting multiple sclerosis (ID827)
- Biotin for primary and secondary progressive multiple sclerosis (ID919)
- Ocrelizumab for treating primary progressive multiple sclerosis (ID938)
- Peg interferon beta 1a for multiple sclerosis (ID1521)
This has led to many publications and presentation at international conferences. See: Armoiry, X., et al. (2018), Chalmers J R, et al. (2014), Melendez-Torres, G. J., et al (2018a), Melendez-Torres, G. J.et al (2017) and Miller, M. A., et al (2010)